top of page

Public Comments

Letters and testimony submitted regarding state PDAB activity

CANN Public Comment: Washington PDAB Ongoing Review Concerns (September 2026)

Publication date: 

9/13/26

CANN urges the Washington PDAB to address process and data concerns in its ongoing drug review cycle, arguing that upper payment limits are ineffective affordability tools that risk adverse outcomes for patients, pharmacies, and 340B-covered entities.

View PDF
CANN Public Comment: Washington PDAB UPL Rulemaking Draft (June 2026)

Publication date: 

6/15/26

CANN submits comments on Washington's proposed UPL rulemaking (WAC 182-52-0010 and 182-52-0100), raising concerns about vague definitions of "excess costs," conflicting UPL scope language, inconsistent methodology standards, and appeals processes that disrupt the physician-patient relationship.

View PDF
CANN Public Comment: Washington PDAB Drug Selection Process

Publication date: 

7/9/25

Comment on Washington PDAB's drug selection process for affordability review, addressing selection methodology and patient access implications.

View PDF

Opinions

Published opinions and op-eds from CANN

Other Healthcare Policy Areas in your state

CANN monitors multiple healthcare policy initiatives across Washington. Explore related programs and learn how you can stay informed and get involved.

bottom of page